Zacks Investment Research
02 Nov 2026, 16:46 UTC · 1h ago
Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?
Impact · against what's priced in
The primary catalyst is the FDA's accelerated approval of Inovio's Voceryq, which introduces direct competition for Precigen's Papzimeos in the RRP market. While Precigen has strong current momentum and upcoming earnings, the emergence of a rival therapy creates a headwind for its projected revenue growth.
- INO+0.80
No priced-in read yet
- In context
The FDA granted accelerated approval to Voceryq for the treatment of RRP on October 30, providing Inovio with a commercial product in a specialized market.
Read from the article alone
Top 1 mover · tap to explore
